Cytomegalovirus prophylaxis in solid organ transplant recipients: the issues (Q33861749)

29 July 2017

1 reference

title

Cytomegalovirus prophylaxis in solid organ transplant recipients: the issues (English)

1 reference

29 July 2017

Legendre C

1

1 reference

29 July 2017

Thervet E

series ordinal

2

1 reference

29 July 2017

language of work or name

English

0 references

publication date

1 March 2000

1 reference

Transplantation Proceedings

29 July 2017

published in

1 reference

29 July 2017

volume

32

1 reference

29 July 2017

issue

2

1 reference

29 July 2017

page(s)

377-378

1 reference

Infection in organ-transplant recipients

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2899%2900984-7

7 January 2021

Cytomegalovirus prophylaxis in solid organ transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2899%2900984-7

7 January 2021

Which renal transplant patients should receive cytomegalovirus immune globulin? A cost-effectiveness analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2899%2900984-7

7 January 2021

Ganciclovir. An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients.

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2899%2900984-7

7 January 2021

Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2899%2900984-7

7 January 2021

Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected].

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2899%2900984-7

7 January 2021

Prophylactic oral ganciclovir compared with deferred therapy for control of cytomegalovirus in renal transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2899%2900984-7

7 January 2021

Cytomegalovirus prophylaxis with antiviral agents in solid organ transplantation: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2899%2900984-7

7 January 2021

Quantitation of cytomegalovirus: methodologic aspects and clinical applications.

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2899%2900984-7

7 January 2021

Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients. A randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2899%2900984-7

7 January 2021

Ganciclovir resistance as a result of oral ganciclovir in a heart transplant recipient with multiple human cytomegalovirus strains in blood

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2899%2900984-7

7 January 2021

The cost impact of cytomegalovirus disease in renal transplant recipients.

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2899%2900984-7

7 January 2021

10.1016/S0041-1345(99)00984-7

Identifiers

DOI

1 reference

29 July 2017

1 reference